drugset / Trial / NCT01004185

Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis

NCT01004185

Phase 3 Terminated 39 enrolled Warner Chilcott
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether low dose Asacol® (27 mg/kg - 71 mg/kg) and high dose Asacol® (53 mg/kg - 118 mg/kg) are safe and effective when dosed as 400 mg delayed-release tablets given twice daily for 26 weeks to children and adolescents for the maintenance of remission of ulcerative colitis.

Timeline

Start
2009-10
Primary completion
2011-03
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Mesalamine Small molecule 1.2 g
Subject Mesalamine Small molecule 2 g
Subject Mesalamine Small molecule 2.4 g
Subject Mesalamine Small molecule 3.6 g
Subject Mesalamine Small molecule 4.8 g

Indications